Clinical Trial

Artificial Intelligence Mapping and Ablation of Non-Pulmonary Vein Electrical Drivers of AF Study

Study acronym: IMPRoVED-AF
Recruiting
View on ClinicalTrials.gov →
Summary
The goal of this clinical trial is to compare the use of the Vektor Computational ECG Mapping System (vMap®) with pulmonary vein isolation (PVI), to using PVI alone, to treat Atrial Fibrillation (AF) in adults. Participants will have a 50/50 or 1 out of 2 chance of being placed in the treatment or control arm. The control arm of the study involves PVI alone for ablation procedure(s). The treatment arm involves the use of vMap mapping in addition to PVI to plan ablation procedure(s).
Protocol Amendment History 3 amendments
This ClinicalTrials.gov record has been amended 3 times since 2025-04-18; most recent amendment 2026-03-12.
Status change: Not Yet Recruiting → Recruiting 2025-06-30
Trial Details
NCT Number NCT06935591
Lead Sponsor Vektor Medical
Collaborators: Veranex Switzerland SA, Veranex
Conditions Atrial Fibrillation (AF)
Enrollment 423 participants
Start Date 2025-06-27
Primary Completion 2027-10 (estimated)
Study Completion 2027-12 (estimated)
Updated on ClinicalTrials.gov 2026-03-16